HiFiBiO Therapeutics

OverviewSuggest Edit

HiFiBiO Therapeutics is a biotherapeutics company. The company integrates deep-rooted biological expertise with its comprehensive single-cell profiling technologies. It allows discovering and advancing a pipeline of antibody drugs to treat cancer and autoimmune disorders.

HQParis, FR

Latest Updates

Employees (est.) (Apr 2021)72(+6%)
Cybersecurity ratingAMore

Key People/Management at HiFiBiO Therapeutics

Liang Schweizer

Liang Schweizer

Chief Executive Officer & Chief Scientific Officer
Jeff He

Jeff He

Chief Operating Officer
Xuqiong Wu

Xuqiong Wu

General Counsel
Show more

HiFiBiO Therapeutics Office Locations

HiFiBiO Therapeutics has offices in Paris, Cambridge and Shanghai
Paris, FR (HQ)
29 Rue du Faubourg Saint-Jacques
Shanghai, CN
1077 Zhangheng Rd, Pudong Xinqu
Cambridge, MA, US
237 Putnam Ave
Show all (3)

HiFiBiO Therapeutics Financials and Metrics

Summary Metrics

Founding Date


HiFiBiO Therapeutics total Funding

$104.5 m

HiFiBiO Therapeutics latest funding size

$67 m

Time since last funding

2 years ago

HiFiBiO Therapeutics investors

HiFiBiO Therapeutics's latest funding round in August 2019 was reported to be $67 m. In total, HiFiBiO Therapeutics has raised $104.5 m
Show all financial metrics

HiFiBiO Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

HiFiBiO Therapeutics Online and Social Media Presence

Embed Graph

HiFiBiO Therapeutics Blogs

Clinical approach and biomarker strategy for HFB301001, a novel OX40 agonistic antibody

Presenters: Ross Fulton, Jinping Gan, Yun-Yueh Lu, Julianna Crivello, Zachery Duda, Zhiyuan Wang, Rebecca Silver, Alexandra Staskus, Charina Ortega, Sami Ellouze, Carine George, Sophie Foulon, Wenhua Xu, Xing Cai, Joyce Pi, Dean Lee, Monika Manne, Ruina Jin, Yuan Wang, Hongkai Zhang, Nicola Beltrami…

HFB9-2, a novel Galectin 9 neutralizing antibody for the treatment of AML and other cancers

Presenters: Germain Margall, Muriel David, Julie Prigent, Dean Lee, Wenhua Xu, Joyce Pi, Xing Cai, Tengfei Wang, Ouyang Li, He Zhou, Andreas Raue, Nicola Beltraminelli, Mingjie Chen, Jia Wu, Mingfang Feng, Angelo Paci, Julia Delahousse, Véronique Saada, Stéphane de Botton, Pierre Busson, Stephanie B…

Mechanism of Action and Biomarker Strategy for HFB200301, an Anti-TNFR2 Agonist Antibody for the Treatment of Cancer

Presenters: Shuo Wei, Ross Fulton, Yun-Yueh Lu, Qian Zhang, He Zhou, Andreas Raue, Mingjie Chen, Wenhua Xu, Xing Cai, Juliana Crivello, Zachary Duda, Zhiyuan Wang, Rebecca Silver, Alexandra Staskus, Charina Ortega, Sami Ellouze, Carine George, Sophie Foulon, Dean Lee, Monika Manne, Nicola Beltramine…

Discovery and characterization of a novel anti-human CXCR5 antibody for the treatment of B cell lymphomas

Presenters: Ayrin Kök, Germain Margallducos, Stephanie Beq, Clarisse Monchecourt, Hombline Poullain, Muriel David, Sami Ellouze, Carine George, Mingjie Chen, Yun-Yueh Lu, Juying Li, Qian Zhang, Jean Wang, Adam Woolfe, Louise Gody, Francisco Adrian, Liang Schweizer, Nicola Beltraminelli HFB1002 progr…

Luigi Manenti, MD joins HiFiBiO Therapeutics as SVP, Global Head of Clinical Development

Luigi Manenti, MD will join the company as Senior Vice President, Global Head of Clinical Development, and become a member of the company’s senior leadership team. CAMBRIDGE, Mass. – April 7th, 2021 – HiFiBiO Therapeutics has brought on Luigi Manenti, MD, to oversee its clinical organization. Dr. Ma…

HiFiBiO Therapeutics to Present Progress on Four Novel Immunotherapy Programs at AACR 2021

HiFiBiO Therapeutics to present four e-posters detailing recent advancements on the following programs: HFB2003, HFB3010, HFB1002, and HFB2009. CAMBRIDGE, Mass. – April 6, 2021 – Scientists at HiFiBiO Therapeutics will share with the scientific community preclinical data for novel monoclonal antibod…
Show more

HiFiBiO Therapeutics Frequently Asked Questions

  • When was HiFiBiO Therapeutics founded?

    HiFiBiO Therapeutics was founded in 2013.

  • Who are HiFiBiO Therapeutics key executives?

    HiFiBiO Therapeutics's key executives are Liang Schweizer, Jeff He and Xuqiong Wu.

  • How many employees does HiFiBiO Therapeutics have?

    HiFiBiO Therapeutics has 72 employees.

  • Who are HiFiBiO Therapeutics competitors?

    Competitors of HiFiBiO Therapeutics include Sphere Fluidics, Biocon Biologics and Xediton.

  • Where is HiFiBiO Therapeutics headquarters?

    HiFiBiO Therapeutics headquarters is located at 29 Rue du Faubourg Saint-Jacques, Paris.

  • Where are HiFiBiO Therapeutics offices?

    HiFiBiO Therapeutics has offices in Paris, Cambridge and Shanghai.

  • How many offices does HiFiBiO Therapeutics have?

    HiFiBiO Therapeutics has 3 offices.